Although the use of TKIs is known to significantly improve survival in patients with EGFR sequence variation–positive NSCLC, their potential cardiotoxicity may threaten benefits in long-term mortality and morbidity.15 Notably, the use of TKIs in Asia is significantly higher than that in the Western countries owing to the high prevalence of the EGFR sequence variation in the Asian population.9 Therefore, it is crucial to understand and weigh the association of TKIs with both survival and cardiovascular outcomes. This evidence concerns the gene EGFR and non-small cell lung carcinoma.